Identification of antibodies specific for lyssaviruses and methods of their use
AssigneeThe Government of the United States of America as represented by the Secretary of the Department of
InventorsTodd G. Smith, Xianfu Wu
Life of this patent
Estimating the term…
Abstract
Described herein is a method of identifying a monoclonal antibody (or antigen-binding fragment thereof) that specifically binds a plurality of lyssaviruses for use in post-exposure rabies prophylaxis or in the treatment of clinical rabies. The method includes using a naïve antibody phage display library to screen for phage clones that bind whole recombinant rabies virus or cells expressing glycoprotein from multiple lyssaviruses (such as RABV, MOKV and WCBV) and/or specifically bind recombinant glycoprotein from different lyssaviruses.
Claims20
An isolated monoclonal antibody, or antigen-binding fragment thereof, that specifically binds at least two different lyssaviruses or that specifically binds glycoprotein from at least two different lyssaviruses, wherein the antibody or antigen-binding fragment thereof comprises a variable heavy (VH) domain complementarity determining region 1 (CDR1), CDR2 and CDR3, and wherein the CDR1, CDR2 and CDR3 are encoded by the CDR1, CDR2 and CDR3 nucleotide sequences of any one of SEQ ID NOs:
- 44-110.
An expression vector comprising a nucleotide sequence at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to the nucleotide sequence of any one of SEQ ID NOs:
- 44-110.
Dependencies are inferred from the claim text.